Summary The search for novel antitumour drugs has reached a plateau phase. The carcinomas remain almost as intractable as they did 40 years ago and the need for effective therapy is pressing. There is an argument that the current pharmacopoeia is sufficient but, to be effective, the biochemical mechanisms of drug resistance must be circumvented. In tackling the question of why certain cancer cells are resistant, the converse question of why others are sensitive still remains to be answered fully. Asking the fundamental question of why and how a cell dies may provide clues as to what avenues lie open for improved chemotherapy. In this review we survey the recent literature on cell death and we argue that it is possible that the outcome of chemotherapy may be determined by the response of the cell to the formation of the drug-target complex, and/or its sequellae, rather than to the biochemical changes brought about by the drug alone. One of these responses, determined by the phenotype of the cell, may be activation of a genetic programme for cell death.
How do cytotoxic drugs kill cells?
Although much is known about the primary mechanisms of action of many anticancer agents including the location of their cellular targets, it is not yet clear how interaction with these targets should lead to sudden or eventual cell death. Recently, it has been suggested that diverse anticancer drugs may induce a mode of cell death which has characteristics of apoptosis, a phenomenon which has been conceptualised as "programmed' cell death (Barry et al., 1990; Dyson et al., 1986; Eastman, 1990; Ijiri & Potten, 1983; Kaufmann, 1989; Lorico et al., 1988; Searle et al., 1975; Yoshioka et al., 1987) . These findings strongly suggest that disparate drug-induced lesions activate a conserved, gene-activated program for cell death. The ability of the cancer cell to mount a 'programmed' cell death, or not, may be an important arbiter of the therapeutic response.
How do cells die?
Several modes of cell death have been described (Wyllie, 1987 (Wyllie, , 1988 Wyllie et al., 1980; Orrenius et al., 1989; Boobis et al., 1989; Lockshin & Beaulaton, 1981; Potten, 1987; Bowen & Bowen, 1990) . Apoptosis, first outlined by Kerr and colleagues (1972) , is a phenomenon which is morphologically defined by cell shrinkage and, notably in epithelial cells, the isolation of a cell from its neighbours by the loss of cell-to-cell contacts. Perhaps most characteristically, there is a specific pattern of chromatin condensation, giving a dense crescentic mass close to the nuclear margin (Arends et al., 1990; Wyllie, 1980) . These processes are followed by the budding off of apoptotic bodies. Apoptotic cells express new surface signal molecules and they are rapidly recognised by phagocytes and engulfed so that the cell dies without inflicting damage to viable neighbours Duvall et al., 1985; Savill et al., 1990) . Apoptosis occurs spontaneously in solid tumours of various types (Wyllie, 1985; Searle et al., 1975; Szende et al., 1989; Sarraf & Bowen, 1988; Kyprianou et al., 1990; Kerr & Searle, 1981; Kerr & Lamb, 1984 is dictated by the balance between cell gain (proliferation) and cell loss (cell death and differentiation) (Steel, 1985) . Cell loss is sometimes considerable and apoptotic cell death is a key player in the equation which predicts tumour size and development. Measurement of apoptotic cells in tumours is difficult to quantify with accuracy since their 'half life' of histologically recognisable apoptosis is short and cell samples are often heterogeneous.
The biochemistry of apoptosis is incompletely defined; it appears to be triggered by a plethora of diverse noxic stimuli when they are presented at concentrations which do not rapidly precipitate metabolic collapse (necrosis -see below). Additionally, apoptosis plays a pivotal role in embryogenesis and in development (Hinchliffe, 1981; Goldman et al., 1983; Nishikawa et al., 1989) . Recent studies suggest that an elevation of cellular calcium is a central event in the activation of a calcium-magnesium-dependent endonuclease which cleaves DNA at regular internucleosomal sites resulting in 180 base pair integer oligonucleosomal fragments (Cohen & Duke, 1984; McConkey et al., 1989a-c and Orrenius et al., 1988 Orrenius et al., , 1989 . This fragmentation is visible as DNA 'ladders' on agarose gels (Arends et al., 1990) . The endonuclease involved in apoptosis is inhibited by zinc. In some but not all cases where death by apoptosis occurs, inhibition of protein synthesis by cycloheximide prevents the appearance of these ladders ; this suggests that proteins instrumental to the process of cell suicide are required, perhaps including those which regulate calcium homeostasis. Paradoxically, there have been reports that cycloheximide induces apoptosis (Searle et al., 1975) . In stark contrast to necrosis, apoptosis is a thermodynamically uphill process which is thought to be genetically modulated.
Necrosis is a thermodynamically down-hill process. Nonphysiological extremes in the external environment of the cell (e.g. hyperthermia and hypoxia) and high concentrations of noxic substances cause a progressive loss in membrane integrity, a collapse of cellular homeostasis and a depletion of ATP levels Judah et al., 1965 ). An early fall in ATP precedes a fatal disruption of the ionic gradients which allow the cell to do work. The cell ruptures to spill out degradative lysosomal enzymes which mediate an inflammatory reaction in the immediate locality. This is not a process which is genetically influenced, and it would seem to be uncontrollable, in terms of possible drug intervention, with the possible exception of drugs which alter tumour vasculature (Denekamp et al., 1982) .
The induction of apoptosis as an antitumour strategy has already gained credibility. Krammer's group have isolated an antibody named anti APO-1 which is reported to induce the regression of B lymphoblastoid tumours (Trauth et al., 1989) and Szende et al. (1989) have used analogs of somatostatin and leutinising hormone-releasing hormone to treat pancreatic and mammary carcinomas by the induction of apoptosis.
The induction of terminal differentiation could be viewed as a long term commitment to death. The mature neutrophil undergoes apoptosis and on the expression of new antigens, is selectively phagocytosed by macrophage (Savill et al., 1989 (Savill et al., , 1990 . Similarly, HL-60 myelomonocytic leukaemia cells differentiated to granulocytes undergo apoptosis (Martin et al., 1990) . There are interesting parallels between the processes of drug-induced apoptosis and drug-induced differentiation. In glucocorticoid-induced cell death of human CCRF-CEM lymphoblastoid cells, a period of 'precommittment' is required before apoptosis is initiated (Yuh & Thompson, 1989 (Hickman & Friedman, 1988) . The period of precommitment for cell death is variable amongst cell types, so that certain cells can respond within a few hours to the apoptotic stimulus and it would seem that in these, the mechanism for programmed cell death is ready 'primed' for activity. For example immature thymocytes initiate apoptosis 4 h after methylprednisolone (Wyllie, 1980) and HL-60 do so 2-4 h after etoposide (Kaufmann, 1989) . A number of studies suggest that the 'precommitment' time for apoptosis to be triggered is related to the cycle time of some cells, as well as to their differentiated status (Ijiri & Potten, 1983 ).
How do drugs induce apoptosis?
Because drugs with widely disparate modes of action as defined by their primary targets, e.g. dihydrofolate reductase inhibitors (Lorico et al., 1988; Kaufman, 1989) , 5-fluorouracil (Dyson et al., 1986; Yoshioka et al., 1987) (Lock & Ross, 1990a,b) . Changes in the activity of specific cell cycle regulated proteins, might therefore represent a common type of 'damage' that provides the initiating event for a cascade leading to cell death. It has been suggested that a sustained alteration of proteins might also be a conserved type of mild 'damage' which is imposed by the wide variety of agents which induce leukaemic cell differentiation (Richards et al., 1988) . It was suggested that an enzyme might become locked by a tightbinding inhibitor into a conformation which was only normally present momentarily in the cell, for example the cleavable complex between topoisomerase II and DNA or the complex between dihydrofolate reductase and its ligand, and that this type of 'damage' or imbalance, together with a reduction of proliferative potential, triggers an adaptive response which engaged a programme of terminal differentiation. The hypothesis, which has temporal aspects associated with it, has parallels with a genetically highly conserved system of detecting damage and responding to it: the activation of the transcription of heat shock genes. Here again, a variety of disparate stimuli, gen8rally which affect protein conformation, activate the highly conserved heat shock response . It has been shown that cells are able to recognise damaged, malfolded proteins and most interestingly, and relevant to the hypothesis above, that abnormal amounts of normally folded proteins are able to activate heat shock gene transcription (Anathan et al., 1986) . It was recently reported that cytotoxic prostaglandins indtdced the synthesis of a heat shock protein, although it was not clear whether the change in synthesis was causatively involved in the fate of the cells (Santoro et al., 1989) . The activation of the heat shock response by damage may be a useful paradigm for considerations of how a cell 'senses' damage, and how it signals for the initiation of transcription, so the heat shock response will be discussed briefly:
The response of the cell to abnormal proteins (generally those which are malfolded) is initiated at the transcriptional level by the activation of a transcription factor which binds to a promoter (the heat shock element). This promotor is downstream from a number of important signal-activated transcriptional elements which may co-regulate its activity (Milarski & Morimoto, 1990) . The synthesis of the heat shock proteins, under conditions of a mild stress, permits the cell to become tolerant to further stress (Riabowol et al., 1988) . It is possible that the heat shock transcription factor acts as a partial signal: when bound to heat shock proteins it has been proposed that it is inactive but when the heat shock proteins become associated with aberrant proteins in the cell it is released and presumably translocated to the nucleus to activate the promoter (Mosser et al., 1990) . The heat shock protein may act as the 'sensor' for cell damage and elegant expeniments to map the recognition domains of the 70 kD heat shock protein have been published recently (Milarski & Morimoto, 1989) . Whether the damage induced by different chemotherapeutic agents is recognised directly (the drugreceptor complex) or as a consequence of this damage, such as the change in cdc2 (Lock & Ross, 1990a,b) , 1989a,b; Cohen & Duke, 1984) .
Moreover, in some cells apoptosis is rapidly evoked by treatment with calcium inophore and is prevented by chelation of calcium (McConkey et al., 1989b) . The calcium channel blocker flunarizine inhibited neuronal cell death after withdrawal of nerve growth factor, but the concentration required was greater than that required to inhibit voltage dependent calcium channels, and its mode of action was suggested to be intracellular, possibly by inhibition of calmodulin, supporting a role for calcium in the activation of apoptosis (Rich & Hollowell, 1990) . It is not obvious how a sustained calcium rise would allow the maintenance of membrane integrity, typical of an apoptotic cell, nor how this type of calcium rise would be initiated by say the presence of transient topoisomerase II-associated DNA double strand breaks (Lock & Ross, 1990a,b; Kaufmann, 1989 ). This does not rule out the important potential of calcium to mediate the initiation of apoptosis but experiments where calcium is elevated artificially by ionophores may be activating just one arm of a complex process.
Genes
What progress has been made in the identification of genes responsible for cell death? A beautiful picture of the involvement of specific genes in 'programmed' cell death has emerged from studies of the development of the nematode Caenorhabditis elegans (Ellis & Horvitz, 1986; Yuan & Horvitz, 1990 ). Here, mutations of the genes ced-3 and ced-4 prevented normal patterns of cell death associated with development. These genes act autonomously within cells which die by apoptosis and in concert with genes which then result in the cleavage of their DNA (nuc 1) and the engulfment of the dying cells (ced-l and ced-2). Interestingly, Hedgecock et al. (1983) have suggested that the endonuclease may be expressed by the engulfing cells in C. elegans. In the rat ventral prostate which undergoes apoptosis after castration due to androgen ablation, the transcriptional cascade c-fos, c-myc and heat shock 70K was observed under temporal conditions paradoxically reminiscent of the activation of both proliferation and differentiation (Buttyan et al., 1988 (Tsujimoto et al., 1985; Williams et al., 1990; Hockenberry et al., 1990; Cotter, 1990) prevents the onset of apoptosis after the withdrawal of IL-3 from IL-3-dependent murine haematopoietic stem cells (Vaux et al., 1988) and protects the cells from the effects of a variety of toxins, including methotrexate (Tsujimoto, 1989) suggests that apoptosis may be negatively modulated by certain genes.
Chemotherapy and cell death (Hickman & Friedman, 1988) . Are there cellular hierarchies which determine the propensity of a cell to undergo apoptosis? In the epithelia of the intestine and in the testis this appears to be the case. The relative promiscuity of the apoptotic response in haemopoietic cells (Wyllie, 1980; Baxter et al., 1989; Smith et al., 1989; Williams et al., 1990; Liu et al., 1989) , which amplify in numbers as they proliferate and differentiate, might be important to prevent the inheritance of damage and its amplification during development. Perhaps surprisingly, haemopoietic stem cells are relatively inefficient at mounting the repair of cellular damage and this lack of repair capacity may predispose them to the alternative pathway of cell death (Figure 1 ). In other cell types where division and differentiation is not associated with a significant amplification of cell numbers, is programmed cell death more difficult to trigger because the cells are programmed with a greater survival potential? If this is the case, as it seems to be in some intestinal epithelial crypt cells (Iriji & Potten, 1983; Bennett et al., 1984) , could it be that the precise nature of the primary target for cytotoxicity is of lesser importance in determining the outcome of therapy than the status of the cell with respect to its ability to engage apoptosis? What the drug-target complex may do is to provide cellular selectivity for the initiation of a response. This aspect of a cellular 'reaction' to the formation of a drug receptor complex, and/or its sequellae, could be viewed as an 'adaptive response'. If apoptosis is viewed as one of the adaptive response repertoires of the cell, alongside the initiation of alternative pathways such as differentiation, the induction of a drug resistance phenotype -which in certain cases may be transient (Lazo & Basu, 1991) , the induction of mechanisms of repair, or drug-induced increases in metastatic potential (McMillan & Hart, 1987) , then not surprisingly the outcome of drug therapy will be determined by the response of the cell, according to its phenotype, rather than by the nature of the primary drug-target interaction alone (see Figure 1 ). Some cells, it seems, may be harder to kill than others, no matter how ingenious the strategy or how novel the drug or drug target, because they have an enhanced survival potential. The existance of genes which modulate the survival potential of cells, such as bcl-2 and components of certain DNA viruses (Gregory et al., 1991) , suggest that it may be possible to selectively influence the ability of a cell to die, hopefully irrespective of its proliferative status and, most importantly for the drug hunter, perhaps irrespective of the precise locus of the stimulus for cell death -the drug-target complex.
